Susquehanna International Group
HCWB icon

Susquehanna International Group’s HCW Biologics HCWB Stock Holding History

Susquehanna International Group’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,345
Closed -$19.5K – 13537
2025
Q4 		$19.5K Buy
+3,345
New +$56.8K ﹤0.01% 11970

Other funds holding HCWB

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's HCWB Position: Q1 2026 in Review

Susquehanna International Group sold out of HCW Biologics (HCWB) in Q1 2026, closing a stake of 3,345 shares — an estimated $19.5K sold.

Susquehanna International Group first reported a position in HCWB in Q4 2025 and held it in 1 quarter. The position peaked at $19.5K in Q4 2025. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • Susquehanna International Group reported no remaining HCW Biologics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 3,345 HCW Biologics shares in Q1 2026, an estimated $19.5K.
  • Susquehanna International Group first reported a position in HCW Biologics in Q4 2025 and held it in 1 quarter.
  • Susquehanna International Group's HCW Biologics position peaked at $19.5K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.